RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Apple Turns 50: From Garage Startup to AI Crossroads 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
SAN RAFAEL, Calif., Oct. 11, 2016 -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 27, at 4:30 p.m. ET to discuss third quarter 2016 financial results and provide a general business update.
Dial-in Number
U.S. / Canada Dial-in Number: (877) 303-6313
International Dial-in Number: (631) 813-4734
Conference ID: 96042296
Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 96042296
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.biomarin.com. A replay of the call will be archived on the site for one week following the call.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.biomarin.com.
Contacts: Investors Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451
